CD19-targeted chimeric antigen receptor (CAR) T cell therapy has provided impressive initial response rates for pediatric and adolescent and young adult (AYA) patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) (1–5). Here, CD19 is linked to B-cell acute lymphoblastic leukemia.